

Discussions with leaders: *JNM* editor-in-chief Johannes Czernin, with Ken Herrmann, continues a series of interviews with leaders in nuclear and molecular imaging and therapy with a conversation with Silke Gillissen, an internationally recognized European oncologist. . . . **Page 169**

ComBat harmonization guide: Orhac and colleagues explain and illustrate with practical examples the use of the ComBat method for harmonization and reduction of imaging “scanner effects” on biomarker values in multicenter studies. . . . **Page 172**

Evaluating LATE: Reiger and Silverman offer commentary on the challenges of differential diagnoses of dementia-related proteinopathy disorders, particularly those associated with frontotemporal lobar degeneration, amyotrophic lateral sclerosis, and limbic-predominant age-related TDP-43 encephalopathy (LATE). . . . **Page 180**

T-cell PET imaging toolbox: Li and colleagues provide a state-of-the-art overview of the applications of T-cell PET imaging and its potential to improve clinical management of cancer immunotherapy and T-cell-driven diseases. . . . **Page 183**

Thyroid cancer standard of care: Avram and colleagues summarize the essential information needed for multidisciplinary management of differentiated thyroid cancer, emphasizing individualization of ^{131}I therapy based on risk of tumor recurrence. . . . **Page 189**

Managing a ^{131}I -MIBG therapy clinic: O’Brien and Pryma discuss the operational aspects of clinical implementation and use of high-specific-activity ^{131}I -MIBG in patients with advanced pheochromocytoma/paraganglioma, including observations from a decade of personal experience. . . . **Page 196**

Imaging biomarkers in PDAC: Benz and colleagues assess ^{18}F -FDG PET/CT as an early and late interim imaging biomarker in patients with pancreatic ductal adenocarcinoma who undergo first-line systemic therapy. **Page 199**

^{131}I -GD2 scintigraphy before RIT: Zhang and colleagues assess tumor targeting and biodistribution of a ^{131}I -labeled chimeric GD2-antibody clone 14/18 in patients with late-stage neuroblastoma, sarcoma, pheochromocytoma, or neuroendocrine tumors to identify eligibility for radioimmunotherapy. **Page 205**

^{68}Ga -FAPI PET/CT in lymphoma: Jin and colleagues profile fibroblast activation proteins in different subtypes of lymphomas and explore the potential utility of ^{68}Ga -FAPI PET/CT in characterizing lesions and extent of disease. . . . **Page 212**

^{177}Lu -DOTATATE in lung NETs: Zidan and colleagues report on the efficacy and safety of ^{177}Lu -DOTATATE in patients with somatostatin receptor-positive lung neuroendocrine tumors. . . . **Page 218**

Tumor sink effect in PSMA PET: Gafita and colleagues determine in an international, multicenter study the impact of tumor burden on ^{68}Ga -PSMA-11 PET biodistribution using quantitative measurements. . . . **Page 226**

aPROMISE standardized PSMA analysis: Nickols and colleagues introduce an automated platform to extend the Prostate Cancer Molecular Imaging Standardized Evaluation criteria in ^{18}F -DCFPyL PET/CT imaging in patients with prostate cancer. . . . **Page 233**

PSMA PET/CT IAEA study: Cerci and an international consortium of researchers report on a prospective multicenter study evaluating the diagnostic performance and clinical impact of PSMA-based PET/CT in biochemical recurrence of prostate cancer. . . . **Page 240**

EAU BCR risk groups and PSMA PET: Dong and colleagues identify associations between PSMA-targeted PET/CT findings and European Association of Urology-defined risk stratification for biochemical recurrence in prostate cancer. . . . **Page 248**

Dose estimation in RLT: Mix and colleagues investigate the value of pretherapeutic kidney function and post-first-cycle dosimetry in predicting cumulative dose at the end of PSMA-based radioligand therapy in prostate cancer. . . . **Page 253**

^{211}At -labeled therapy for prostate cancer: Mease and colleagues detail synthesis of and initial preclinical investigations with a new ^{211}At -labeled radiotracer targeting PSMA in prostate cancer. . . . **Page 259**

Post-COVID PET/CT in lung disease: Gheysens and colleagues look at current experience and limited data on the value of ^{18}F -FDG PET/CT in COVID-19 lung disease sequelae and preview related articles in this issue of *JNM*. . . . **Page 268**

PET/CT findings after COVID-19: Thornton and colleagues describe experience with the temporal evolution of pulmonary ^{18}F -FDG uptake in patients with COVID-19 and post-COVID-19 lung disease. . . . **Page 270**

COVID-19 PET and CT lung changes: Wakfie-Corieh and colleagues explore the potential added diagnostic value of ^{18}F -FDG PET/CT in asymptomatic cancer patients with suspected COVID-19 pneumonia by investigating associations between metabolic and structural changes in lung parenchyma. . . . **Page 274**

^{18}F -FDG PET in vasculitis: Dashora and colleagues evaluate the performance of qualitative and semiquantitative scoring methods for ^{18}F -FDG PET assessment in images from patients with large-vessel vasculitis. . . **Page 280**

Hippocampal eA β and tau PET: Raman and colleagues investigate whether early-frame amyloid PET correlates with the presence of tau pathology in a study group of amyloid-positive and -negative patients. . . . **Page 287**

Linearization of receptor availability: Khodaii and colleagues determine the accuracy and precision of 3 widely used linearizations of receptor availability (saturation, inhibition, and occupancy plots) in molecular imaging with PET. . . . **Page 294**

^{11}C -PiB versus ^{124}I -antibody PET: Meier and colleagues compare an antibody-based PET ligand targeting nonfibrillar amyloid- β with ^{11}C -PiB after β -secretase inhibition in Alzheimer disease mouse models of advanced-stage amyloid- β pathology. . . . **Page 302**

^{68}Ga -NODAGA-exendin-4 PET/CT in focal CHI: Boss and colleagues compare the performance of this new radiolabeled exendin-4 tracer with that of ^{18}F -DOPA PET/CT in preoperative detection of focal congenital hyperinsulinism. . . . **Page 310**

Standard methods for dose calculations: Stabin and colleagues present standardized methods for collecting data to be used in radiopharmaceutical dose calculations, with steps that can be used as a template for calculating radiation dose estimates from animal or human data. . . . **Page 316**